Kestin (Ebastine)

Ebastine is an H1‑antihistamine used to manage allergic disorders by blocking peripheral histamine receptors.

• Allergic rhinitis: reduces sneezing, nasal congestion, and itching caused by seasonal or perennial allergens.
• Seasonal allergic rhinitis: provides relief during pollen seasons by limiting histamine‑mediated nasal symptoms.
• Chronic idiopathic urticaria: diminishes wheal formation and itching in patients with persistent hives of unknown cause.

• Ebastine selectively binds to peripheral H1 histamine receptors, preventing histamine from attaching to these sites. By blocking the receptor, it inhibits the cascade that leads to increased vascular permeability, edema, and sensory nerve stimulation, thereby reducing the classic signs of allergic reactions such as itching, swelling, and rhinorrhea.

Adverse reactions may occur with any antihistamine therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Dry mouth: sensation of oral dryness.
• Drowsiness: occasional mild sedation.
• Fatigue: feeling of reduced energy.
• Nausea: mild gastrointestinal upset.
• Abdominal pain: transient discomfort.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm requiring medical attention.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Anaphylaxis: acute, potentially life‑threatening allergic response.
• Hepatic injury: signs of liver dysfunction.
• Blood dyscrasias: abnormal blood counts.
• Persistent dizziness: lasting beyond initial dosing.

Safety considerations should be reviewed before initiating therapy.

• Assess renal function: adjust use if severe impairment is present.
• Monitor hepatic status: avoid in patients with significant liver disease.
• Caution with sedation: avoid operating machinery if drowsiness occurs.
• Avoid in known hypersensitivity: discontinue if allergic reaction develops.
• Pregnancy and lactation: consult a physician before use.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Potential drug interactions may affect efficacy or safety.

Major Interactions (Avoid)

• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ebastine plasma levels.
• Other sedating antihistamines: additive drowsiness risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Alcohol: may enhance central nervous system depression.
• CNS depressants (e.g., benzodiazepines): monitor for increased sedation.
• Anticholinergic agents: may worsen dry mouth.